BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 32497116)

  • 1. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia.
    Rockhold M; Kunkel L; Lacoste JL; Szymanski T; Rothenberg P; Zimmerman P; Minc S
    J Vasc Surg; 2024 Jun; 79(6):1466-1472.e1. PubMed ID: 38278371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
    Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
    Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
    Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Rationale for the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study.
    Dimond M; Looby M; Shah B; Sinha SS; Isseh I; Rollins AT; Abdul-Aziz AA; Kennedy J; Tang DG; Klein KM; Casselman S; Vermeulen C; Sheaffer W; Snipes M; O'connor CM; Shah P
    J Card Fail; 2024 Jun; 30(6):819-828. PubMed ID: 37956897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
    J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
    [No Abstract]   [Full Text] [Related]  

  • 9. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
    Desai NR; Krumme AA; Schneeweiss S; Shrank WH; Brill G; Pezalla EJ; Spettell CM; Brennan TA; Matlin OS; Avorn J; Choudhry NK
    Am J Med; 2014 Nov; 127(11):1075-1082.e1. PubMed ID: 24859719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020.
    Iyer GS; Tesfaye H; Khan NF; Zakoul H; Bykov K
    JAMA Netw Open; 2023 Mar; 6(3):e234059. PubMed ID: 36947039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
    Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
    Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of clinical settings, indications and consequences of measurement of direct oral anticoagulant plasma levels in Northern Tasmania, Australia.
    Lim MS; Mohamed M
    Intern Med J; 2024 Jun; 54(6):932-940. PubMed ID: 38213182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network.
    Martin KA; Lancki N; Kreuziger LB; Li C; Eyster ME; Sanfilippo K; Woller SC; Rosovsky RP
    Thromb Res; 2023 Sep; 229():146-148. PubMed ID: 37454464
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation.
    Schapkaitz E; Ter Morshuizen B; Mc Cree M; F Jacobson B
    Clin Appl Thromb Hemost; 2024; 30():10760296241249167. PubMed ID: 38659339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
    Huisman MV; Ferreira M; Feuring M; Fraessdorf M; Klok FA
    J Thromb Haemost; 2018 Sep; 16(9):1775-1778. PubMed ID: 29974611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.